A closely watched experimental vaccine targeting pancreatic cancer has stumbled in a mid-stage clinical study, sending shares of its developer plummeting.
Elicio Therapeutics reported that its KRAS cancer vaccine failed to improve patient outcomes in a Phase 2 trial, according to Endpoints News. The vaccine was designed to train the immune system to recognize and attack cancer cells carrying mutations in the KRAS gene — one of the most common and notoriously difficult-to-treat drivers of pancreatic cancer.
Despite the disappointing results, Elicio is not walking away. The company says it is actively seeking funding to advance the program into a larger Phase 3 trial, a move that signals confidence in the underlying science even as investors reacted harshly to the data.
Pancreatic cancer is among the deadliest of all cancers, with a five-year survival rate that has historically hovered in the low single digits. The disease is often caught late, and existing treatments offer limited benefit, making the search for new approaches especially urgent. Vaccines that can prime the immune system against tumor-specific mutations like KRAS have long been considered a promising frontier — but translating that promise into clinical success has proven elusive.
The failure adds to a string of setbacks in the cancer vaccine space, though the field has also seen renewed interest following breakthroughs in mRNA technology. Elicio's decision to push toward Phase 3 despite Phase 2 disappointment will test whether investors share that conviction.
If a KRAS-targeting vaccine can eventually be proven to work, it could open the door to a new class of treatments for one of the cancers most in need of better options.